adplus-dvertising
Connect with us

Business

Liberals confident U.S. AstraZeneca vaccines will be delivered despite Biden's 'America first' strategy – National Post

Published

 on


Anand said she does not yet have a specific delivery timeline and also did not mention any specific promises from the U.S. administration to allow the shipments

Article content

OTTAWA — Despite the U.S. government’s insistence vaccines made in America should go into American arms first, Procurement Minister Anita Anand says she is confident Canada will receive 20 million doses of the newly approved AstraZeneca vaccine from U.S. plants.

Anand said she has received assurances from AstraZeneca that Canada’s order will be delivered between April and September and that the Biden administration’s stance will not interfere with shipments.

“(AstraZeneca) has not seen any problems with the export doses to Canada. In addition, we’ve spoken with our embassy to ensure that those doses will be leaving the United States and we have no reason to doubt that they will be coming into this country.” she said.

Getting to Canada might only be the first hurdle. Complicating the issue further are the vaccine’s shorter expiry period and conflicting expert advice on just who should get the shot.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

Anand said she does not yet have a specific delivery timeline and also did not mention any specific promises from the U.S. administration to allow the shipments.

U.S. President Joe Biden’s press secretary, Jen Psaki, was asked Monday if the U.S. administration would be open to sharing vaccines with Mexico and she insisted they are focused on vaccines within their borders.

“The president has made clear that he is focused on ensuring that vaccines are available to every American. That is our focus,” she said.

  1. A nurse prepares to administer a dose of the AstraZeneca COVID-19 vaccine at Dobong health care centre on Feb. 26, 2021 in Seoul, South Korea.

    Canada shouldn’t use AstraZeneca COVID vaccine on seniors, national panel advises

  2. Vaccines won't come of the line at this under-construction National Research Council of Canada facility in Montreal until at least December.

    Why Canada is at the mercy of vaccine nationalism during the COVID pandemic

Doses of the Pfizer vaccine are made just across the U.S. border, in Michigan, but Canada receives its Pfizer shipments from Belgium because the U.S. signed an agreement ensuring doses from the U.S. plant go to Americans first.

Anand said Canada has dealt with American export issues before and ultimately prevailed, citing the reversal of the Trump administration’s decision last year to prevent the export of 3M N95 masks.

“We are ensuring that they will be delivered here across the border just like we did with the N95 back in the spring.”

In addition to the American doses, Canada will receive two million doses of AstraZeneca produced in India, with 500,000 arriving as early as Wednesday.

The new doses have a shorter than normal shelf life, with 300,000 of them expiring within 30 days and the remainder of the two million doses likely to expire within 60 days of delivery.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

Moreover, the National Advisory Committee on Immunization (NACI) recommended Monday the vaccine not be used for people over the age of 65 because of a limited amount of clinical trial evidence of its effectiveness in that age group.

The recommendation is at odds with the official regulatory approval from Health Canada, which authorized the vaccine in all age groups.

Four provinces — Alberta, British Columbia, Ontario and Prince Edward Island — have already said they would not administer AstraZeneca to anyone over age 65.

Faced with the expiration issue, provincial governments will need to move quickly to decide who will receive these vaccines, but Anand said she is confident they are up to the challenge.

“It is important to recognize that we have high demand for vaccines in this country,” she said. “We have provinces and territories that have repeatedly told the federal government that they want vaccines as soon as possible, and they’re ready to administer vaccines as soon as possible.”

Conservative Health Critic Michelle Rempel Garner called for an emergency health committee meeting to sort out the issue. She said Canadians deserve to understand the seemingly contradictory decisions.

“Conflicting advice from NACI and Health Canada on whether or not the AstraZeneca vaccine is sufficiently effective in this population must be clarified before the vaccine is delivered to the provinces and Canadians deserve to understand the impacts of this decision,” said Rempel Garner in a statement.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

Some countries in Europe have made similar recommendations to focus the AstraZeneca vaccine on younger people, but the U.K. has given the shot to everyone. France after initially giving it only to those under 65 reversed course Monday and will now give it to all age groups.

Health Canada’s chief medical adviser, Dr. Supriya Sharma, said on Friday when announcing the vaccine’s approval that they had limited clinical trial data, but they also had real-world experience from millions of people who have now received the vaccine.

“There is evidence to show that in the older age group, it would be effective, especially at preventing severe disease and hospitalizations.”

She said for seniors the benefits clearly outweigh the risks of walking around unvaccinated, which is why Health Canada gave it the green light. But she said it was up to NACI and the provinces to decide which vaccines best fit which populations.

Dr. Theresa Tam said she expected NACI’s recommendations would change over time as they saw more data from the company and more real-world evidence on the vaccine’s effectiveness.

“As they see more and more of that real world data accumulating that will be adjusted as well.”

-with files from the Canadian Press 

• Email: rtumilty@postmedia.com | Twitter:

Comments

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Business

Japan’s SoftBank returns to profit after gains at Vision Fund and other investments

Published

 on

 

TOKYO (AP) — Japanese technology group SoftBank swung back to profitability in the July-September quarter, boosted by positive results in its Vision Fund investments.

Tokyo-based SoftBank Group Corp. reported Tuesday a fiscal second quarter profit of nearly 1.18 trillion yen ($7.7 billion), compared with a 931 billion yen loss in the year-earlier period.

Quarterly sales edged up about 6% to nearly 1.77 trillion yen ($11.5 billion).

SoftBank credited income from royalties and licensing related to its holdings in Arm, a computer chip-designing company, whose business spans smartphones, data centers, networking equipment, automotive, consumer electronic devices, and AI applications.

The results were also helped by the absence of losses related to SoftBank’s investment in office-space sharing venture WeWork, which hit the previous fiscal year.

WeWork, which filed for Chapter 11 bankruptcy protection in 2023, emerged from Chapter 11 in June.

SoftBank has benefitted in recent months from rising share prices in some investment, such as U.S.-based e-commerce company Coupang, Chinese mobility provider DiDi Global and Bytedance, the Chinese developer of TikTok.

SoftBank’s financial results tend to swing wildly, partly because of its sprawling investment portfolio that includes search engine Yahoo, Chinese retailer Alibaba, and artificial intelligence company Nvidia.

SoftBank makes investments in a variety of companies that it groups together in a series of Vision Funds.

The company’s founder, Masayoshi Son, is a pioneer in technology investment in Japan. SoftBank Group does not give earnings forecasts.

___

Yuri Kageyama is on X:

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Trump campaign promises unlikely to harm entrepreneurship: Shopify CFO

Published

 on

 

Shopify Inc. executives brushed off concerns that incoming U.S. President Donald Trump will be a major detriment to many of the company’s merchants.

“There’s nothing in what we’ve heard from Trump, nor would there have been anything from (Democratic candidate) Kamala (Harris), which we think impacts the overall state of new business formation and entrepreneurship,” Shopify’s chief financial officer Jeff Hoffmeister told analysts on a call Tuesday.

“We still feel really good about all the merchants out there, all the entrepreneurs that want to start new businesses and that’s obviously not going to change with the administration.”

Hoffmeister’s comments come a week after Trump, a Republican businessman, trounced Harris in an election that will soon return him to the Oval Office.

On the campaign trail, he threatened to impose tariffs of 60 per cent on imports from China and roughly 10 per cent to 20 per cent on goods from all other countries.

If the president-elect makes good on the promise, many worry the cost of operating will soar for companies, including customers of Shopify, which sells e-commerce software to small businesses but also brands as big as Kylie Cosmetics and Victoria’s Secret.

These merchants may feel they have no choice but to pass on the increases to customers, perhaps sparking more inflation.

If Trump’s tariffs do come to fruition, Shopify’s president Harley Finkelstein pointed out China is “not a huge area” for Shopify.

However, “we can’t anticipate what every presidential administration is going to do,” he cautioned.

He likened the uncertainty facing the business community to the COVID-19 pandemic where Shopify had to help companies migrate online.

“Our job is no matter what comes the way of our merchants, we provide them with tools and service and support for them to navigate it really well,” he said.

Finkelstein was questioned about the forthcoming U.S. leadership change on a call meant to delve into Shopify’s latest earnings, which sent shares soaring 27 per cent to $158.63 shortly after Tuesday’s market open.

The Ottawa-based company, which keeps its books in U.S. dollars, reported US$828 million in net income for its third quarter, up from US$718 million in the same quarter last year, as its revenue rose 26 per cent.

Revenue for the period ended Sept. 30 totalled US$2.16 billion, up from US$1.71 billion a year earlier.

Subscription solutions revenue reached US$610 million, up from US$486 million in the same quarter last year.

Merchant solutions revenue amounted to US$1.55 billion, up from US$1.23 billion.

Shopify’s net income excluding the impact of equity investments totalled US$344 million for the quarter, up from US$173 million in the same quarter last year.

Daniel Chan, a TD Cowen analyst, said the results show Shopify has a leadership position in the e-commerce world and “a continued ability to gain market share.”

In its outlook for its fourth quarter of 2024, the company said it expects revenue to grow at a mid-to-high-twenties percentage rate on a year-over-year basis.

“Q4 guidance suggests Shopify will finish the year strong, with better-than-expected revenue growth and operating margin,” Chan pointed out in a note to investors.

This report by The Canadian Press was first published Nov. 12, 2024.

Companies in this story: (TSX:SHOP)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

RioCan cuts nearly 10 per cent staff in efficiency push as condo market slows

Published

 on

 

TORONTO – RioCan Real Estate Investment Trust says it has cut almost 10 per cent of its staff as it deals with a slowdown in the condo market and overall pushes for greater efficiency.

The company says the cuts, which amount to around 60 employees based on its last annual filing, will mean about $9 million in restructuring charges and should translate to about $8 million in annualized cash savings.

The job cuts come as RioCan and others scale back condo development plans as the market softens, but chief executive Jonathan Gitlin says the reductions were from a companywide efficiency effort.

RioCan says it doesn’t plan to start any new construction of mixed-use properties this year and well into 2025 as it adjusts to the shifting market demand.

The company reported a net income of $96.9 million in the third quarter, up from a loss of $73.5 million last year, as it saw a $159 million boost from a favourable change in the fair value of investment properties.

RioCan reported what it says is a record-breaking 97.8 per cent occupancy rate in the quarter including retail committed occupancy of 98.6 per cent.

This report by The Canadian Press was first published Nov. 12, 2024.

Companies in this story: (TSX:REI.UN)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending